Filtered By:
Therapy: Statin Therapy

This page shows you your search results in order of date. This is page number 10.

Order by Relevance | Date

Total 220 results found since Jan 2013.

The Media, Mixed Messages and Statins
By SAURABH JHA, MD Recently, sitting next to me at a family friend’s wedding, was a middle-aged Indian male, a retired investment banker. He had an axe to grind with doctors. He said, “You doctors don’t know what you’re talking about. One doctor says check your PSA, and another doctor says don’t bother. Can’t you doctors make up your minds?” He was an aggressive chap, faux aggression really; a tardive alpha male, who’d looked like he’d been hen-pecked most of his life. He had just eaten four pieces of rasmalai, and was storming the fifth. Rasmalai is a sugar-rich Indian desert that’s monstrously tasty ...
Source: The Health Care Blog - July 4, 2016 Category: Consumer Health News Authors: John Irvine Tags: Uncategorized Source Type: blogs

Media, Mixed Messages and Statins
By SAURABH JHA, MD Recently, sitting next to me at a family friend’s wedding, was a middle-aged Indian male, a retired investment banker. He had an axe to grind with doctors. He said, “You doctors don’t know what you’re talking about. One doctor says check your PSA, and another doctor says don’t bother. Can’t you doctors make up your minds?” He was an aggressive chap, faux aggression really; a tardive alpha male, who’d looked like he’d been hen-pecked most of his life. He had just eaten four pieces of rasmalai, and was storming the fifth. Rasmalai is a sugar-rich Indian desert that’s monstrously tasty ...
Source: The Health Care Blog - July 4, 2016 Category: Consumer Health News Authors: John Irvine Tags: Uncategorized Source Type: blogs

Time For Cardiologists To Start Prescribing Diabetes Drugs?
There’s an emerging consensus that now may be the time for cardiologists to start thinking seriously about prescribing diabetes drugs. Until now most cardiologists have not considered this to be part of their job description. But now new data from large cardiovascular outcome trials (CVOTs) shows that these drugs may one day become, like statins and...Click here to continue reading...
Source: CardioBrief - June 22, 2016 Category: Cardiology Authors: Larry Husten Tags: Diabetes Policy & Ethics Prevention, Epidemiology & Outcomes Uncategorized diabetes drugs empagliflozin liraglutide Source Type: blogs

Fight Aging! Newsletter, June 6th 2016
This study teaches us that poor wound healing and wrinkling and sagging that occur in aging skin share similar mechanisms." Reduced cell cohesiveness of outgrowths from eccrine sweat glands delays wound closure in elderly skin Human skin heals more slowly in aged vs. young adults, but the mechanism for this delay is unclear. In humans, eccrine sweat glands (ESGs) and hair follicles underlying wounds generate cohesive keratinocyte outgrowths that expand to form the new epidermis. Our results confirm that the outgrowth of cells from ESGs is a major feature of repair in young skin. Strikingly, in aged skin, ...
Source: Fight Aging! - June 5, 2016 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Does A ‘One-Size-Fits-All’ Formulary Policy Make Sense?
Over the last decade, insurers have increasingly used step therapy, or “fail-first,” policies as a strategy to contain pharmaceutical costs. Step therapy requires patients to begin treatment for a medical condition on a typically less expensive drug, and only progress to more costly second-line drugs when the first-line therapy becomes ineffective or inappropriate. Step therapy shifts clinical decision-making away from physicians and toward centralized policies that define treatment steps for patient populations based on the potential for more cost-effective care. The rapid growth in the use of step therapy policies in...
Source: Health Affairs Blog - June 2, 2016 Category: Health Management Authors: Adrienne Chung, Joanna MacEwan and Dana Goldman Tags: Costs and Spending Drugs and Medical Technology Equity and Disparities Health Policy Lab Health Professionals Insurance and Coverage Payment Policy Quality Prescription Drugs step therapy Source Type: blogs

Nanoparticles to Target Atherosclerotic Plaques
This popular science article takes a look at efforts to develop nanoparticles capable of reducing the size of plaques in blood vessels produced by the processes of atherosclerosis. These plaques narrow and deform blood vessels, ultimately breaking apart to cause blockages and ruptures of blood vessels that are often fatal. Atherosclerosis is caused at root by damaged lipids that enter the circulation and lodge in blood vessel tissue. This is followed by an unfortunate set of self-reinforcing signals sent by cells in the blood vessel wall and then by immune cells that turn up to try to deal with the problem. When immune cel...
Source: Fight Aging! - May 31, 2016 Category: Research Authors: Reason Tags: Daily News Source Type: blogs

Actually, Medical Errors are the Leading Cause of Death
By SAURABH JHA, MD Josef Stalin famously said: one death is a tragedy; one million is a statistic. Perhaps 250, 000 preventable deaths from medical errors, according to an analysis by Makary and Daniel in the BMJ, maketh a Stalin. The problem with Makary’s analysis, which also concluded that medical errors are the third leading cause of death, isn’t the method. Yes, the method is shaky. It projects medical errors from a series of thirty five patients to a country of 320 million, which is like deciding national spice tolerance on what my family eats for dinner. The problem with Makary’s analysis isn’t that it is ful...
Source: The Health Care Blog - May 10, 2016 Category: Consumer Health News Authors: John Irvine Tags: THCB Source Type: blogs

More on the gambling decision to take statins
In my last post, I wrote my initial thoughts of an important new study on how the decision to take a medication or have a screening test in the name of prevention is similar to playing the lottery. I promised to think and write about the study more carefully. My latest thoughts are now published over at  theheart.org|Medscape Cardiology. Here is the intro: Medicine is easier when people are sick. In treating heart attack or stroke, certainty rules over uncertainty. The best outcome of a heart attack or stroke, however, is not to have had one. Prevention is where medicine gets hard, very hard. To prevent something that may...
Source: Dr John M - March 30, 2016 Category: Cardiology Authors: Dr John Source Type: blogs

A new way to discuss statin drugs
A new study published last week in an open heart journal changes the conversation about how patients and doctors think about and discuss preventive therapies–such as statins. Dr. Richard Lehman may be the smartest doctor on Twitter. This is what he said: This is a game-changer https://t.co/WgGdLlodbL — Richard Lehman (@RichardLehman1) March 20, 2016 Most discussions about using statin drugs focus on a 5-10 year period. That’s not the right way to discuss these drugs. When we take a statin drug (or screen for cancer, or any other preventive intervention) we do it to live longer–not just 5-10 years. ...
Source: Dr John M - March 21, 2016 Category: Cardiology Authors: Dr John Source Type: blogs

Rare Disease Day is Here!
It's finally come; the rare day that comes every four years, Rare Disease Day. For the past several weeks, leading up to February 29, I've been blogging about rare diseases. The basic theme of all my blogs is that the rarity of rare diseases is not a numeric accident. The rare diseases form a distinct class of diseases having a distinct set of unifying biological properties that distinguish them from common diseases. In the past 30 years, most of the great advances of medicine have been in the realm of the rare diseases; not the common diseases. In many cases, progress in the common diseases has come as a secondary gain f...
Source: Specified Life - February 29, 2016 Category: Information Technology Tags: common diseases complex diseases funding for rare disease research medical research orphan diseases orphan drugs rare disease day zebra diseases Source Type: blogs

Guideline-Centered Care
By JOHNATHON TOMLINSON, MD Doreen, Ahmed and Henry have recently had their medication changed in response to a new guideline for prescribing Statins, cholesterol-lowering drugs. None of them came to ask for a change in their medication. In each case the change was recommended by a clinician in response to a new guideline against which our practice will be judged and financially rewarded or penalised. Here are the NICE guidelines 2015: The NICE guideline on lipid modification recommends that the decision whether to start statin therapy should be made after an informed discussion between the clinician and the person about ...
Source: The Health Care Blog - January 30, 2016 Category: Consumer Health News Authors: John Irvine Tags: Featured NHS Source Type: blogs

DM / DNB Cardiology Entrance Mock Test 3
Please wait while the activity loads. If this activity does not load, try refreshing your browser. Also, this page requires javascript. Please visit using a browser with javascript enabled. If loading fails, click here to try again Click on the 'Start' button to begin the mock test. After answering all questions, click on the 'Get Results' button to display your score and the explanations. Start Congratulations - you have completed DM / DNB Cardiology Entrance Mock Test 3. You scored %%SCORE%% out of %%TOTAL%%. Your performance has been rated as %%RATING%% Your answers are hi...
Source: Cardiophile MD - January 17, 2016 Category: Cardiology Authors: Prof. Dr. Johnson Francis, MD, DM, FACC, FRCP Edin, FRCP London Tags: General Cardiology Source Type: blogs

Overdiagnosis and Overtreatment
I’ve never been more concerned about the harms of healthcare. Any exposure to the health care system can get you in trouble. It’s especially scary when healthy people enter the system–often in the name of prevention. Remember that the most likely outcome of a medical intervention in a person without complaints is harm. How can we make a person who says he is well any better? The newest scourge is the treatment of risk factors–not diseases. It’s routine for me to see people admitted to the hospital because of side effects from drugs or procedures used to treat risk factors. This morning, thanks...
Source: Dr John M - January 15, 2016 Category: Cardiology Authors: Dr John Source Type: blogs

The Dismal Science Behind Financial Incentives For Docs
This study should give pause to anyone who thinks that physicians can be manipulated with more money.  They live by more than bread alone.
Source: The Health Care Blog - January 12, 2016 Category: Consumer Health News Authors: John Irvine Tags: THCB Uncategorized Source Type: blogs

Alzheimer’s disease and macular degeneration concerns with Entresto
Three academic physicians, writing in an editorial in the Journal of the American Medical Association, raised serious (but theoretical) concerns about the risk of Alzheimer’s disease and macular degeneration with long-term use of the new heart failure drug, valsartan/sacubitril (Entresto, Novartis). Here is the translation: Sacubitril is a drug that inhibits neprilysin, which is an enzyme (protein) responsible for breaking down things called natriuretic peptides (other proteins). This is good for heart failure patients because having more natriuretic peptides may prevent worsening heart muscle weakness. The problem i...
Source: Dr John M - January 7, 2016 Category: Cardiology Authors: Dr John Source Type: blogs